What is Lightcast?
Lightcast operates at the intersection of microfluidics and precision medicine, providing a next-generation platform that redefines how researchers culture, control, and assay cellular material. The company's market position is bolstered by its successful pilot studies with leading pharmaceutical entities and academic institutions, which have validated the platform's ability to accelerate the development of novel therapies. By simplifying the complexity of cell analysis, Lightcast is not merely a tool provider but a strategic partner in the ongoing biology revolution, facilitating breakthroughs in synthetic biology and molecular diagnostics.
How much funding has Lightcast raised?
Lightcast has raised a total of $77.5M across 3 funding rounds:
Seed
$1.5M
Series B
$49M
Unspecified
$27M
Seed (2019): $1.5M, investors not publicly disclosed
Series B (2023): $49M led by Omx Ventures, Illumina Ventures, Merck Ventures, and ARCH Venture Partners
Unspecified (2026): $27M supported by Illumina Ventures, Longwall Ventures, Omx Ventures, ARCH Venture Partners, and Merck Ventures
Key Investors in Lightcast
Omx Ventures
A biotechnology investment firm that focuses on transforming groundbreaking discoveries into scalable companies by leveraging data, bio-tools, and artificial intelligence.
Illumina Ventures
A leader in genomics and precision health investing, dedicated to building an ecosystem that translates capital into innovation to enhance human health.
Merck Ventures
The strategic corporate venture capital arm of Merck, investing globally in transformational ideas and technologies that impact core business areas.
What's next for Lightcast?
With this major strategic investment, Lightcast is well-positioned to scale its operations and deepen its penetration into the global life sciences market. The company's roadmap likely involves expanding its commercial footprint and further refining its microfluidic capabilities to support more complex, high-throughput clinical applications. As the industry shifts toward more personalized and data-driven medicine, Lightcast's ability to provide unprecedented control over cellular environments will be critical in maintaining its competitive advantage. Future growth will likely focus on translating these technological advancements into standardized, scalable solutions for the broader biopharmaceutical ecosystem.
See full Lightcast company page
